Gilead Sciences (GILD) Liabilities and Shareholders Equity (2009 - 2026)

Gilead Sciences has reported Liabilities and Shareholders Equity for 18 years, with the latest figure at $56.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity changed 0.28% year-over-year to $56.3 billion; the trailing twelve-month figure through Mar 2026 stood at $229.6 billion (up 2.69% YoY), and the FY2025 full-year result was $59.0 billion, changed 0.05% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $56.3 billion, down from $59.0 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $63.2 billion in Q4 2022, with the low at $53.6 billion in Q2 2024.
• Historically, Liabilities and Shareholders Equity has averaged $59.4 billion across 5 years, with a median of $59.0 billion in 2025.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity declined 14.05% — and 2025, when it advanced 7.35%.
• Gilead Sciences' Liabilities and Shareholders Equity stood at $63.2 billion in 2022, then fell by 1.66% to $62.1 billion in 2023, then dropped by 5.04% to $59.0 billion in 2024, then climbed by 0.05% to $59.0 billion in 2025, then declined by 4.65% to $56.3 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $56.3 billion (Q1 2026), $59.0 billion (Q4 2025), and $58.5 billion (Q3 2025), per Business Quant data.